@article{b0c217c9382f47cc95dbdccbb74f5ebf,
title = "Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: A subanalysis of a multicenter, open-label phase I/II study",
abstract = "We recently conducted an open-label phase I/II study to evaluate the efficacy and safety of preoperative and chronic treatment with metyrosine (an inhibitor of catecholamine synthesis) in pheochromocytoma/paraganglioma (PPGL) in Japan. We compared creatinine-corrected metanephrine fractions in spot urine and 24-hour urine samples (the current standard for the screening and diagnosis of PPGLs) from 16 patients to assess the therapeutic effect of metyrosine. Percent changes from baseline in urinary metanephrine (uMN) or normetanephrine (uNMN) were compared between spot and 24-hour urine samples. Mean percent changes in uMN or uNMN in spot and 24-hour urine were –26.36% and –29.27%, respectively. The difference in the percent change from baseline between uMN or uNMN in spot and 24-hour urine was small (–2.90%). The correlation coefficient was 0.87 for percent changes from baseline between uMN or uNMN measured in spot and 24-hour urine. The area under the receiver operator characteristic (ROC) curve of uMN or uNMN measured in spot urine vs. 24-hour urine (reference standard) to assess the efficacy of metyrosine treatment was 0.93. Correlations and ROCs between 24-hour urinary vanillylmandelic acid, adrenaline, and noradrenaline and 24-hour uMN or uNMN were similar to those between spot uMN or uNMN and 24-hour uMN or uNMN. No large difference was observed between spot and 24-hour urine for the assessment of metyrosine treatment by quantifying uMN or uNMN in Japanese patients with PPGLs. These results suggest that spot urine samples may be useful in assessing the therapeutic effect of metyrosine.",
keywords = "24-hour urine sample, Metanephrine, Metyrosine, Normetanephrine, Spot urine sample",
author = "Kazuhiro Takekoshi and Fumitoshi Satoh and Akiyo Tanabe and Takahiro Okamoto and Atsuhiro Ichihara and Mika Tsuiki and Takuyuki Katabami and Masatoshi Nomura and Tomoaki Tanaka and Tadashi Matsuda and Tsuneo Imai and Masanobu Yamada and Suguru Asada and Nobuyuki Kawata and Mitsuhide Naruse",
note = "Funding Information: Kazuhiro Takekoshi received research funding from Blue Industries Inc. Fumitoshi Satoh received honoraria from Takeda Pharmaceutical Co. Ltd.; research funding from Fujirebio Inc., FUJIFILM Wako Pure Chemical Corporation, Japan Agency for Medical Research and Development, Nippon Boehringer Ingelheim Co. Ltd., MSD K.K., Mochida Pharmaceutical Co. Ltd., Fuji Yakuhin Co. Ltd., Kowa Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., and Teijin Pharma Ltd.; and scholarship donations from Novartis Pharma K.K., Novo Nordisk, Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Bayer Yakuhin Ltd., Daiichi Sankyo Company Ltd., Teijin Pharma Ltd., Sumitomo Dainippon Pharma Co. Ltd., and JCR Phar-? maceuticals Co. Ltd. Akiyo Tanabe received research funding from Ono Pharmaceutical Co. Ltd. Takahiro Okamoto received a scholarship donation from Taiho Pharmaceutical Co. and ?isai Co. Ltd. Atsuhiro Ichihara received honoraria from Mochida Pharmaceutical Co. Funding Information: Ltd. Takuyuki Katabami received a scholarship donation from Sanofi K.K. Masatoshi Nomura received honoraria from Ono Pharmaceutical Co. Ltd., Taishotoyama Phar-? maceutical Co. Ltd., Novo Nordisk Pharma Co. Ltd., MSD K.K., Chugai Pharmaceutical Co. Ltd., and Sanofi K.K.; research funding from Astellas Pharma Inc., and scholarship donations from Taishotoyama Pharmaceuti-? cal Co. Ltd. and Ono Pharmaceutical Co. Ltd. Tadashi Matsuda received research funding from Ono Pharma-? ceutical Co. Ltd. Suguru Asada and Nobuyuki Kawata are employees of Ono Pharmaceutical Co. Ltd. Mika Tsuiki, Tomoaki Tanaka, Tsuneo Imai, Masanobu Yamada and Mitsuhide Naruse have no conflicts of inter-? est to declare. Funding Information: This work was funded by Ono Pharmaceutical Co., Ltd. (Osaka, Japan).",
year = "2019",
doi = "10.1507/endocrj.EJ19-0125",
language = "English",
volume = "66",
pages = "1063--1072",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "12",
}